Management of IBD during the COVID-19 outbreak: resetting clinical priorities

Silvio Danese; Maurizio Cecconi; Antonino Spinelli

doi:10.1038/s41575-020-0294-8

Management of IBD during the COVID-19 outbreak: resetting clinical priorities

Nat Rev Gastroenterol Hepatol. 2020 May;17(5):253-255. doi: 10.1038/s41575-020-0294-8.

Authors

Silvio Danese^{1

2}, Maurizio Cecconi^{3

4}, Antonino Spinelli^{3

5}

Affiliations

¹ IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS -, Humanitas University, Rozzano, Milan, Italy. [email protected].
² Humanitas University, Department of Biomedical Sciences, Rozzano, Milan, Italy. [email protected].
³ Humanitas University, Department of Biomedical Sciences, Rozzano, Milan, Italy.
⁴ Humanitas Clinical and Research Center - IRCCS -, Department of Anaesthesia and Intensive Care, Rozzano, Milan, Italy.
⁵ Humanitas Clinical and Research Center - IRCCS -, Division of Colon and Rectal Surgery, Rozzano, Milan, Italy.

Abstract

The coronavirus disease (COVID-19) worldwide outbreak has led to a dramatic challenge for all healthcare systems, including inflammatory bowel disease (IBD) centres. Here, we describe the fast changes and clinical issues that IBD specialists could face during this SARS-CoV-2 infection pandemic, highlighting the potential rearrangements of care and resetting of clinical priorities.

MeSH terms

COVID-19
Coronavirus Infections / epidemiology*
Humans
Immunologic Factors / therapeutic use
Inflammatory Bowel Diseases / drug therapy
Inflammatory Bowel Diseases / immunology
Inflammatory Bowel Diseases / therapy*
Italy / epidemiology
Pandemics
Pneumonia, Viral / epidemiology*
Practice Guidelines as Topic
World Health Organization

Substances

Immunologic Factors